Strike Out Cancer with the Jimmy Fund ›
Fundraising Events and Programs
What’s New
Research and Patient Care
February 03, 2023
A novel antibody drug-conjugate therapy has been granted accelerated approved by the FDA for the treatment of metastatic HR+, HER2- breast cancer, based on the results of a Dana-Farber study.
more ›
January 20, 2023
Based on findings from a Dana-Farber-led study, the FDA recently approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with certain types of leukemia.
more ›
